Tc-99m Generator

• It is a Tc-99m Pertechnetate form eluted from the generator, it is used intraveneously in thyroid, salivary gland, cerebral, cardiac, and vascular, lacrimal duct, gastrointestinal hemorrhage, arthro-scintigraphy, organ perfusion scintigraphy, and ectopic gastric mucosa localization. Additionally, it is used for labeling the kits containing various carrier agents.
• Content : Mo-99/Tc-99m generator contains fission product Molibdenium-99 (Mo-99) adsorbed on aluminum oxide (Al₂O₃) in a glass column.
• Having half-life of 6 hours.
• Available activity : 10 - 16 GBq

Quotation

I-131 Oral Solution

• Used in thyroid cancer, toxic nodular goiter, toxic diffuse goiter diseases, and hyperthyroidism for treatment purposes also used in thyroid scanning for diagnostic purposes.
• Content : Oral solution in vial contains fission product radioactive iodine (I-131) as an active substance.
• Having half-life of 8,02 days.
• Available activity : 0,37 - 7,4 GBq

Quotation

I-131 Oral Capsule

• Used in thyroid cancer, toxic nodular goiter, toxic diffuse goiter diseases, and hyperthyroidism for treatment purposes also used in thyroid scanning for diagnostic purposes. Used for diagnosis and treatment of thyroid diseases.
• Content : Oral capsule contains the fission product, radioactive iodine (I-131) as an active substance.
• Having half-life of 8,02 days
• Available activity : 0,37 – 7,4 GBq

Quotation

MIBG I-131 Diagnostic

• Used for verification of diagnosis of primary or metastatic pheochromocytomas and neuroblastomas; staging of the disease; monitoring after chemotherapy; early detection of recurrences and planning of MIBG I-131 treatment.
• Content : Sterile, clear, and colorless I-131 iobenguane sulphate solution in its lead shield.
• Available activity : 37 - 74 MBq

Quotation

MIBG I-131 Therapeutic

• Used for the local, lesion-specific treatment of neuroectodermal/ neuroendocrine tumors, in particular pheochromocytoma, neuroblastoma, paraganglioma, medullar thyroid carcinoma, and carcinoid tumor.
• Content : In lead armor, sterile, clear and colorless or slightly yellow (I-131) iobenguane sulfate solution.
• Available activity : 1,85 – 3,7 GBq

Quotation

C.A Lutetium Chloride 177 (Lu-177 C.A)

• Used for the treatment of prostate cancer and neuroendocrine tumors.
• Content : Radiopharmaceutical Precursor Solution containing Lutetium (Lu-177) Chloride C.A and hydrochloric acid and water as excipients.
• Having half-life of 6,648 days.
• Available activity : 1,85 – 18,5 GBq

Quotation

N.C.A Lutetium Chloride 177 (Lu-177 N.C.A)

• Used in the treatment of prostate cancer by binding to PSMA, a cell membrane protein found in prostate cancer cells. Lutetium (Lu-177) is used in the treatment of neuroendocrine tumors by binding to DOTATE, which is a peptide that binds to the sensing receptor known as somatostatin on the surface of neuroendocrine tumors.
• Chemical Form : LuCl3
• Solvent 0.05 M HCl
• pH : 1.0 -2.0
• Content : Radiopharmaceutical Precursor Solution containing Lutetium (Lu-177) Chloride N.C.A ≥ 99.9 % as LuCl₃.
• Having half-life of 6,65 days.
• Decay Mode : Beta Decay Emax= 0.498 MeV The most prominent gamma photon has an energy of 0.208 MeV.
• Available activity : 1,85 – 18,5 GBq

Quotation

Samarium (Sm-153)

• Samarium-153 is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled bisphosphonates on bone scans. The presence of osteoblastic metastases which take up technetium (99mTc)-labelled bisphosphonates should be confirmed prior to therapy.

Quotation